A meta-analysis showed that the overexpression of glucose transporter protein 1 (GLUT1) in solid cancers is linked to the poor prognosis of many tumor types, suggesting that direct GLUT1 targeting could be a promising treatment strategy for solid cancers (59). This evidence concerns the gene SLC2A1 and neoplasm.